As a medical professional, you may encounter patients with bladder tumors. One of the common treatment options for this condition is transurethral resection of bladder tumor (TURBT). This procedure involves removing the tumor through the urethra using a surgical instrument called a cystoscope. While TURBT has its benefits in treating bladder tumors, it also poses some risks that may affect your patients' recovery and overall well-being. In this blog post, we'll delve into the benefits and risks of TURBT so you can better understand how to guide your patients towards making an informed decision about their treatment plan.
While TURBT is a common treatment option for bladder tumors, it's important to recognize that the procedure does pose some risks. One of the most common complications associated with TURBT is bleeding. The cystoscope used in the surgery can damage blood vessels in the bladder, causing excessive bleeding. In some cases, this may require further surgery or even a blood transfusion.
Additionally, patients may experience urinary tract infections (UTIs) after undergoing TURBT. This can be due to bacteria entering the bladder through the urethra during or after surgery. UTIs can cause pain and discomfort and may require antibiotics to treat.
Another potential risk of TURBT is perforation of the bladder wall. If not done correctly, removing a tumor from within the bladder could cause a hole in its walls leading to urine leakage into other parts of your body.
Transurethral Resection of Bladder Tumor (TURBT) is a surgical procedure that involves removing tumors in the bladder using a resectoscope. Although there are risks involved, this procedure also has several benefits.
Another benefit of TURBT is that it can be used as part of a larger treatment plan for more advanced cases of bladder cancer. By removing as much tumor tissue as possible, this procedure can reduce symptoms such as pain and discomfort while also improving overall quality of life.
Because TURBT is minimally invasive, patients typically experience less pain and shorter recovery times than with traditional open surgery. Most patients are able to return home on the same day or within a few days after surgery.
Although there are risks associated with any medical procedure, Transurethral Resection of Bladder Tumor offers several benefits for those suffering from bladder cancer.
Transurethral Resection of Bladder Tumor (TURBT) is a common surgical procedure used to remove bladder tumors. This surgery can be performed under general or local anesthesia, and it typically takes about an hour to complete.
During the procedure, the surgeon inserts a cystoscope, which is a thin tube with a light and camera attached, into the patient's urethra. The scope allows the surgeon to visualize inside the bladder and identify any tumors that need to be removed.
Once identified, the surgeon will use specialized instruments passed through the cystoscope to remove as much of the tumor as possible. In some cases, additional treatments such as laser therapy or chemotherapy may also be done during this time.
Afterwards, patients usually stay in recovery for several hours before being discharged home. It's important for patients to follow post-operative instructions carefully in order to minimize complications such as bleeding or infection.
Transurethral resection of bladder tumor is a common and effective procedure for removing tumors in the bladder. While it does carry some risks, such as bleeding or infection, these are generally rare and can be managed with proper care. The benefits of this procedure far outweigh the potential risks, as it allows patients to quickly recover from their symptoms and return to their daily lives.
1.
Report provides global picture of wide inequalities in care for women's cancers
2.
Cardiorespiratory fitness lowers the risk of colon, lung, and prostate cancer in MEN and lowers mortality from these diseases.
3.
Browse the NBE-Released Curriculum at FNB Head and Neck Oncology.
4.
Unexplained CAR-T Death; Americans Spurn Sunscreen; Improving Diversity in Trials
5.
Is Chemotherapy via Peripheral IV Access More Effective Than Central Lines for Testicular Cancer?
1.
Understanding Dasatinib: A Promising Drug for Cancer Treatment
2.
Hematopoietic Recovery Potential and Long-Term Survival: Mechanisms, Clinical Impact, and Emerging Directions
3.
Immune Escape Landscapes in Solid Tumors
4.
Advancements in Breast Cancer Treatment: From Chemotherapy to Immunotherapy
5.
Progressive Models in Hematology for Healthcare Excellence
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
Thromboprophylaxis In Medical Settings- An Update
3.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
4.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
5.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation